BioAge Labs, Inc. BIOA 深 沪
等待开盘 01-15 09:30:00 美东时间
22.92
+2.230
+10.78%
华盛通- 最 高23.60
- 今 开20.38
- 成交量 105.59万股
- 最 低 20.38
- 昨 收 20.69
- 总市值 8.22亿
- 52周最高 23.60
- 市盈率 静 --
- 换手率 2.94%
- 52周最低 2.88
- 委 比 69.23%
- 总股本 3585.50万
- 历史最高 26.62
- 量 比 0.85
- 振 幅 15.56%
- 历史最低 0.156
- 每 手 1
- 风险率 3.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 娱乐集团TryHard单日狂升138%！Moderna大涨17%，业绩指引超预期
双重利好催化！娱乐集团TryHard单日狂升138%；Moderna股价大涨17%，业绩指引超预期，预计2026年实现10%收入增长>>
01-14 14:20
美股牛股 | 私人航空公司UP单日暴涨46%！One Stop大涨29%，获美军预生产订单
私人航空公司UP单日暴涨46%！One Stop股价涨29%，获美军预生产订单；BIOA涨逾27%，核心在研药获突破进展>>
01-13 17:24
Why Penguin Solutions Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Shares of Penguin Solutions Inc (NASDAQ:PENG) rose sharply in pre-market tradin...
01-07 18:36
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
2025-12-25 00:06
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
BioAge Labs Data From BGE-102 Study Shows Well-Tolerance, Strong Target Engagement In Patients With Cardiovascular Risk Factors
BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced positive
2025-12-04 22:06
Bioage Labs Q3 EPS $(0.56) Beats $(0.58) Estimate, Sales $2.054M
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.58) by 3.45 percent. This is a 91.64 percent increase over losses of $(6.70) per share from the
2025-11-07 06:05
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
2025-10-30 14:22
Citigroup Maintains Buy on Bioage Labs, Raises Price Target to $15
Citigroup analyst Samantha Semenkow maintains Bioage Labs (NASDAQ:BIOA) with a Buy and raises the price target from $10 to $15.
2025-10-30 03:55
Health Canada Approves Leqembi for Early Alzheimer’s Treatment
An announcement from BioArctic AB Class B ( ($SE:BIOA.B) ) is now available. He...
2025-10-27 08:02
